ClinicalTrials.gg
CompletedNCT00162370Updated Mar 15, 2021Results posted

A Study of Stress Echocardiography in Post-Menopausal Women at Risk for Coronary Disease

A Phase 4 interventional study of Perflutren Lipid Microsphere Injectable Suspension in Coronary Artery Disease and Heart Disease, sponsored by Lantheus Medical Imaging. Completed at 3 sites in United States. Open to female participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-03-15.

Sponsored by Lantheus Medical Imaging (part of Lantheus Holdings, Inc.) · Phase 4, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
400
Allocation
Not applicable
Ages
40 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,105 studies in Coronary Artery Disease with a site in United States — 101 open to participants now, 146 under way, 10 of them phase 3. Coronary Artery Disease · United States.

Enrollment
180th of 746
400 · median 107
Started
2004
with 22 others
Phase 4
141 of 1,105
10 open now
Registered
51st of 1,105
by date

Among the 1,105 studies in Coronary Artery Disease with a site in United States, this one is the 180th largest by enrollment of the 746 interventional ones that give a count, is one of 23 that started in 2004, is one of 141 in phase 4, and was the 51st registered.

Coronary Artery Disease

4,863 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

101 of the 1,105 studies in Coronary Artery Disease with a site in United States are open now. Recruiting first, the newest first:

96 more — sign in →

All 101 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 588 Coronary Artery Disease studies recruiting now, 402 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 40 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,105 studies in Coronary Artery Disease with a site in United States, or all of them as a file.
02

Study summary

The study is designed to see if stress echocardiography can be used as a screening exam in peri-, or post-menopausal women with a risk of developing of coronary artery disease and experiencing future cardiac events.

Read the detailed description

The clinical trial is designed to determine the prognostic value of stress echocardiography as a screening examination in peri-, or post-menopausal female patients with an intermediate likelihood of coronary artery disease (CAD) based on risk factors to identify patients at higher risk of experiencing future cardiac events.Female patients who are able to adequately exercise will undergo a symptom-limited exercise echocardiogram. Patients who are unable to adequately exercise or are predicted to be unable to exercise adequately (because of orthopedic/neurologic limitations, lung disease or debility), will perform dobutamine stress echocardiography. All patients will receive DEFINITY at rest and stress to enhance wall motion assessment.

03

Conditions studied

  • Coronary Artery Disease
  • Heart Disease
04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Peri or Post menopausal women either:

    • without symptoms but with risk factors for heart disease OR
    • experiencing atypical chest pain, OR
    • experiencing exertional dyspnea AND 2 or more risk factors for CAD
  • Must be able to perform an exercise stress test

Peri-or (including surgical menopause) based on history.

  • Post-menopausal is defined as females age 40-65 who self-report the absence of menstrual periods for at least 12 months.
  • Peri-menopausal is defined as females age 40-65 who self-report the absence or irregularity of menstrual periods for 6-12 months.
  • Surgical menopause is defined as females who have had a bilateral salpingo-oophorectomy with or without hysterectomy.

Exclusion criteria

Exclusion Criteria:

  • Previous confirmed heart disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 4
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
400 participants (actual)

Study arms

  • Experimental
    Definity

    All patients will undergo a gray scale baseline unenhanced imaging session (apical 2- or 4 chamber view), as well as a DEFINITY (Perflutren Lipid Microsphere Injectable Suspension)-enhanced rest and a DEFINITY enhanced exercise or dobutamine stress echocardiography imaging session. The unenhanced and DEFINITY-enhanced rest and stress echocardiography imaging sessions will be performed on the same day. For the DEFINITY-enhanced imaging sessions all patients will receive diluted DEFINITY intravenously (IV). Diluted DEFINITY will be prepared by mixing 1 mL of activated DEFINITY® with 9 mL of normal saline in a 10 mL syringe.

    Drug: Perflutren Lipid Microsphere Injectable Suspension

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Abnormal Contrast Stress Echocardiography and With Future Major Adverse Cardiac Events (MACE) at 2 and 5 Years Follow-Up

    Peri- or post-menopausal female participants with an intermediate pre-test likelihood of coronary artery disease (CAD) received a Definity contrast-enhanced stress echocardiography study at baseline using either treadmill exercise or dobutamine stresss. Images were evaluated for wall motion abnormalities. The results were compared to patient history on 2-year and 5-year follow up to identify the potential of stress echocardiography for predicting those at higher risk of experiencing future cardiac events. Major adverse cardiac events (MACE) are defined as * Cardiac death * Myocardial infarction * Cardiac revascularization (PCI or CABG) * Hospitalization for chest pain or to rule out myocardial infarction * Development of typical angina * Development of heart failure

    Time frame: 2 year and 5 year follow up

Secondary outcomes

  1. Number of Participants With Abnormal ECG and With Major Adverse Cardiac Events (MACE) at 2 Year Follow-Up

    Prognostic value of stress ECG testing for identifying female patients at increased risk of major adverse cardiac events (MACE) at 2-year follow-up Peri- or post-meopausal female subjects with an intermediate pre-test likelihood of coronary artery disease (CAD) received resting ECG at baseline. ECG was evaluated as normal or abnormal. The results were compared to patient history on 2-year follow up to identify the potential for ECG to predict those at higher risk of experiencing future cardiac events. Major adverse cardiac events (MACE) are defined as * Cardiac death * Myocardial infarction * Cardiac revascularization (PCI or CABG) * Hospitalization for chest pain or to rule out myocardial infarction * Development of typical angina * Development of heart failure

    Time frame: 2-year follow-up

  2. Change in Brain Natriuretic Peptide (BNP) in Subjects With and Without Major Adverse Cardiac Events at 2-year Follow-up.

    The value of exercise-induced changes in blood concentration of cardiac peptide, brain natriuretic peptide (BNP in pg/mL in blood), was assessed in identifying patients with cardiac events at 2-year follow-up. The change in mean BNP blood concentration from rest to stress at baseline is summarized using number of subjects with and without MACE at 2-year follow-up Major adverse cardiac events (MACE) are defined as * Cardiac death * Myocardial infarction * Cardiac revascularization (PCI or CABG) * Hospitalization for chest pain or to rule out myocardial infarction * Development of typical angina * Development of heart failure

    Time frame: 2 year follow up

  3. Change in Atrial Natriuretic Peptide (ANP) in Subjects With and Without Major Adverse Cardiac Events at 2-year Follow-up.

    The value of exercise-induced changes in blood concentration of cardiac peptide, atrial natriuretic peptide (ANP in pg/mL in blood), was assessed in identifying patients with cardiac events at 2-year follow-up. The change in mean ANP blood concentration from rest to stress at baseline is summarized using number of subjects with and without major adverse cardiac events (MACE) at 2-year follow-up. Major adverse cardiac events (MACE) are defined as * Cardiac death * Myocardial infarction * Cardiac revascularization (PCI or CABG) * Hospitalization for chest pain or to rule out myocardial infarction * Development of typical angina * Development of heart failure

    Time frame: 2 year follow up

  4. Change in Brachial Artery Reactivity Was Assessed in in a Subset of Participants With and Without Major Adverse Cardiac Events at 2-year and 5-year Follow-up.

    A subset of the study population of peri- or post-meopausal female participants with an intermediate pre-test likelihood of coronary artery disease (CAD) was assessed for brachial artery reactivity at baseline. Brachial diameter was assessed using ultrasound and a pressure cuff both before and after administration of sublingual nitroglycerin. The results were compared to patient history on 2-year and 5-year follow up to identify the potential for brachial artery reactivity to predict those at higher risk of experiencing future cardiac events.The brachial artery reactivity was summarized using number of subjects with and without MACE on follow-up. Major adverse cardiac events (MACE) are defined as * Cardiac death * Myocardial infarction * Cardiac revascularization (PCI or CABG) * Hospitalization for chest pain or to rule out myocardial infarction * Development of typical angina * Development of heart failure

    Time frame: 2 year and 5 year follow up

  5. Mean Baseline Calcium Score of Participants With and Without Major Cardiac Events at 2-year Follow up.

    Coronary artery calcium scoring assesses calcification of the coronary arteries using electron-beam computed tomography (EBCT). It is a sum of lesion scores of area and density above a threshold density. There is no intrinsic upper limit to the calcium score but values above 1000 may not be measurable. A subset of peri- or post-meopausal females with an intermediate pre-test likelihood of coronary artery disease (CAD) received resting EBCT at baseline. Images were evaluated for calcium score and results compared to patient history on 2-year follow up, Mean calcium score with confidence interval was summarized for subjects with and without major cardiac events (MACE) at 2-year follow up. Calcium score for general population: Score Description Relative Risk 0 No evidence of CAD 0 1-112 Average Risk of CAD 1.9 100-400 Moderate risk of CAD 4.3 400-999 High risk of CAD 7.2 1000 Very high risk of CAD 10.8

    Time frame: 2 year follow up

  6. The Presence of Wall Motion Abnormalities on Definity Stress Echocardiography Assessed for Participants With Both Normal and Abnormal Angiography

    In the sub-set of efficacy-evaluable participants who underwent clinically indicated coronary angiography, the accuracy of exercise echocardiography vs. angiography was determined for the detection of CAD. Positive angiography was defined as any stenosis greater than or equal to 50% in any vessel. Wall motion index change indicating abnormal motion was defined as greater than or equal to 13% in 2 or more segments. Angiography was required to have taken place within 60 days following stress echocardiography.

    Time frame: 60 days

  7. Participants With Positive and Negative Angiography Compared With Their ECG Results

    In the sub-set of efficacy-evaluable participants who underwent clinically indicated coronary angiography, the accuracy of exercise ECG vs. angiography was determined for the detection of CAD. Positive angiography was defined as any stenosis greater than or equal to 50% in any vessel.

    Time frame: 60 days

  8. Number of Participants With Abnormal ECG and With Future Major Adverse Cardiac Events (MACE) at 5 Years Follow-Up

    Prognostic value of stress ECG testing for identifying female patients at increased risk of major adverse cardiac events (MACE) at 5-year follow-up Peri- or post-meopausal female participants with an intermediate pre-test likelihood of coronary artery disease (CAD) received resting ECG at baseline. ECG was evaluated as normal or abnormal. The results were compared to patient history on 5-year follow up to identify the potential for ECG to predict those at higher risk of experiencing future major adverse cardiac events (MACE) at 5-year follow up. Major adverse cardiac events (MACE) are defined as * Cardiac death * Myocardial infarction * Cardiac revascularization (PCI or CABG) * Hospitalization for chest pain or to rule out myocardial infarction * Development of typical angina * Development of heart failure

    Time frame: 5 year follow up

  9. Change in Brain Natriuretic Peptide (BNP) in Participants With and Without Major Adverse Cardiac Events at 5-year Follow-up.

    The value of exercise-induced changes in blood concentration of the cardiac peptide, brain natriuretic peptide (BNP in pg/mL in blood), was assessed in identifying patients with cardiac events at 5-year follow-up. The change in mean BNP blood concentration at baseline from rest to stress is summarized using number of participants with and without MACE at 5-year follow up. Major adverse cardiac events (MACE) are defined as * Cardiac death * Myocardial infarction * Cardiac revascularization (PCI or CABG) * Hospitalization for chest pain or to rule out myocardial infarction * Development of typical angina * Development of heart failure

    Time frame: 5 year follow up

  10. Change in Atrial Natriuretic Peptide (ANP) in Participants With and Without Major Adverse Cardiac Events at 5-year Follow-up.

    The baseline value of exercise-induced changes in blood concentration of the cardiac peptide, atrial natriuretic peptide (ANP in pg/mL in blood), was assessed in identifying patients with cardiac events at 5-year follow-up. The change in mean ANP blood concentration from rest to stress at baseline was summarized using number of subjects with and without major adverse cardiac events (MACE) at 5-year follow up. Major adverse cardiac events (MACE) are defined as * Cardiac death * Myocardial infarction * Cardiac revascularization (PCI or CABG) * Hospitalization for chest pain or to rule out myocardial infarction * Development of typical angina * Development of heart failure

    Time frame: 5 year follow up

  11. Mean Calcium Score of Participants With and Without Major Cardiac Events at 5-year Follow up.

    Coronary artery calcium scoring assesses calcification of the coronary arteries using electron-beam computed tomography (EBCT). It is a sum of lesion scores of area and density above a threshold density. There is no intrinsic upper limit to the calcium score but values above 1000 may not be measurable. A subset of peri- or post-meopausal females with an intermediate pre-test likelihood of coronary artery disease (CAD) received resting EBCT at baseline. Images were evaluated for calcium score and results compared to patient history on 5-year follow up, Mean calcium score with confidence interval was summarized for subjects with and without major cardiac events (MACE) at 5-year follow up Calcium score for general population: Score Description Relative Risk 0 No evidence of CAD 0 1-112 Average Risk of CAD 1.9 100-400 Moderate risk of CAD 4.3 400-999 High risk of CAD 7.2 1000 Very high risk of CAD 10.8

    Time frame: 5 year follow up

07

Results

Posted Dec 8, 2016

Participant flow

Completed Echocardiography Imaging
Participant flow — Completed Echocardiography Imaging
MilestoneDefinity
Started366
Completed366
Not completed0
Efficacy Population
Participant flow — Efficacy Population
MilestoneDefinity
Started366
Completed315
Not completed51
Withdrew: Lost to follow-up51

Outcome measures

PrimaryNumber of Participants With Abnormal Contrast Stress Echocardiography and With Future Major Adverse Cardiac Events (MACE) at 2 and 5 Years Follow-Up

Peri- or post-menopausal female participants with an intermediate pre-test likelihood of coronary artery disease (CAD) received a Definity contrast-enhanced stress echocardiography study at baseline using either treadmill exercise or dobutamine stresss. Images were evaluated for wall motion abnormalities. The results were compared to patient history on 2-year and 5-year follow up to identify the potential of stress echocardiography for predicting those at higher risk of experiencing future cardiac events. Major adverse cardiac events (MACE) are defined as * Cardiac death * Myocardial infarction * Cardiac revascularization (PCI or CABG) * Hospitalization for chest pain or to rule out myocardial infarction * Development of typical angina * Development of heart failure

Time frame:
2 year and 5 year follow up
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Contrast Stress Echocardiography and With Future Major Adverse Cardiac Events (MACE) at 2 and 5 Years Follow-Up
ParticipantsDefinity
Abnormal contrast stress echo and any major cardiac event at 2 year follow up2
Normal contrast stress echo and any major cardiac event at 2 year follow up1
Abnormal contrast stress echo and any major cardiac event at 5 year follow up1
Normal contrast stress echo and any major cardiac event at 5 year follow up5
Statistical analysis
  • Definity · Regression, Cox · p = 0.014
SecondaryNumber of Participants With Abnormal ECG and With Major Adverse Cardiac Events (MACE) at 2 Year Follow-Up

Prognostic value of stress ECG testing for identifying female patients at increased risk of major adverse cardiac events (MACE) at 2-year follow-up Peri- or post-meopausal female subjects with an intermediate pre-test likelihood of coronary artery disease (CAD) received resting ECG at baseline. ECG was evaluated as normal or abnormal. The results were compared to patient history on 2-year follow up to identify the potential for ECG to predict those at higher risk of experiencing future cardiac events. Major adverse cardiac events (MACE) are defined as * Cardiac death * Myocardial infarction * Cardiac revascularization (PCI or CABG) * Hospitalization for chest pain or to rule out myocardial infarction * Development of typical angina * Development of heart failure

Time frame:
2-year follow-up
Reported as:
Count of participants · Participants
Number of Participants With Abnormal ECG and With Major Adverse Cardiac Events (MACE) at 2 Year Follow-Up
ParticipantsDefinity
Number of subjects with abnormal stress ECG at baseline who had MACE at 2 years3
Number of subjects with abnormal stress ECG at baseline who did not have MACE at 2 years15
Statistical analysis
  • Definity · Regression, Cox · p = <0.0001
SecondaryChange in Brain Natriuretic Peptide (BNP) in Subjects With and Without Major Adverse Cardiac Events at 2-year Follow-up.

The value of exercise-induced changes in blood concentration of cardiac peptide, brain natriuretic peptide (BNP in pg/mL in blood), was assessed in identifying patients with cardiac events at 2-year follow-up. The change in mean BNP blood concentration from rest to stress at baseline is summarized using number of subjects with and without MACE at 2-year follow-up Major adverse cardiac events (MACE) are defined as * Cardiac death * Myocardial infarction * Cardiac revascularization (PCI or CABG) * Hospitalization for chest pain or to rule out myocardial infarction * Development of typical angina * Development of heart failure

Time frame:
2 year follow up
Reported as:
Mean · pg/mL
Change in Brain Natriuretic Peptide (BNP) in Subjects With and Without Major Adverse Cardiac Events at 2-year Follow-up.
pg/mLDefinity
Change of BNP from rest to stress in subjects without major cardiac events at 2 year followup5.2 (0.61 to 9.79)
Change of BNP from rest to stress in subjects with major cardiac events at 2 year followup10.7 (-32.5 to 53.9)
SecondaryChange in Atrial Natriuretic Peptide (ANP) in Subjects With and Without Major Adverse Cardiac Events at 2-year Follow-up.

The value of exercise-induced changes in blood concentration of cardiac peptide, atrial natriuretic peptide (ANP in pg/mL in blood), was assessed in identifying patients with cardiac events at 2-year follow-up. The change in mean ANP blood concentration from rest to stress at baseline is summarized using number of subjects with and without major adverse cardiac events (MACE) at 2-year follow-up. Major adverse cardiac events (MACE) are defined as * Cardiac death * Myocardial infarction * Cardiac revascularization (PCI or CABG) * Hospitalization for chest pain or to rule out myocardial infarction * Development of typical angina * Development of heart failure

Time frame:
2 year follow up
Reported as:
Mean · pg/mL
Change in Atrial Natriuretic Peptide (ANP) in Subjects With and Without Major Adverse Cardiac Events at 2-year Follow-up.
pg/mLDefinity
Change of ANP from rest to stress in subjects without major cardiac events at 2-year follow-up5.9 (-98.81 to 110.61)
Change of ANP from rest to stress in subjects with major cardiac events at 2-year follow-up101 (-716.32 to 918.32)
SecondaryChange in Brachial Artery Reactivity Was Assessed in in a Subset of Participants With and Without Major Adverse Cardiac Events at 2-year and 5-year Follow-up.

A subset of the study population of peri- or post-meopausal female participants with an intermediate pre-test likelihood of coronary artery disease (CAD) was assessed for brachial artery reactivity at baseline. Brachial diameter was assessed using ultrasound and a pressure cuff both before and after administration of sublingual nitroglycerin. The results were compared to patient history on 2-year and 5-year follow up to identify the potential for brachial artery reactivity to predict those at higher risk of experiencing future cardiac events.The brachial artery reactivity was summarized using number of subjects with and without MACE on follow-up. Major adverse cardiac events (MACE) are defined as * Cardiac death * Myocardial infarction * Cardiac revascularization (PCI or CABG) * Hospitalization for chest pain or to rule out myocardial infarction * Development of typical angina * Development of heart failure

Time frame:
2 year and 5 year follow up
Reported as:
Number · Percentage
Change in Brachial Artery Reactivity Was Assessed in in a Subset of Participants With and Without Major Adverse Cardiac Events at 2-year and 5-year Follow-up.
PercentageDefinity
Mean %change of brachial artery diameter from rest to stress in subjects w/o MACE at 2 year followup7.8 (4.33 to 11.27)
Mean %change of brachial artery diameter from rest to stress in subjects w/o MACE at 5 year followup7.3 (4.32 to 10.28)
SecondaryMean Baseline Calcium Score of Participants With and Without Major Cardiac Events at 2-year Follow up.

Coronary artery calcium scoring assesses calcification of the coronary arteries using electron-beam computed tomography (EBCT). It is a sum of lesion scores of area and density above a threshold density. There is no intrinsic upper limit to the calcium score but values above 1000 may not be measurable. A subset of peri- or post-meopausal females with an intermediate pre-test likelihood of coronary artery disease (CAD) received resting EBCT at baseline. Images were evaluated for calcium score and results compared to patient history on 2-year follow up, Mean calcium score with confidence interval was summarized for subjects with and without major cardiac events (MACE) at 2-year follow up. Calcium score for general population: Score Description Relative Risk 0 No evidence of CAD 0 1-112 Average Risk of CAD 1.9 100-400 Moderate risk of CAD 4.3 400-999 High risk of CAD 7.2 1000 Very high risk of CAD 10.8

Time frame:
2 year follow up
Reported as:
Mean · score on a scale (calcium score)
Mean Baseline Calcium Score of Participants With and Without Major Cardiac Events at 2-year Follow up.
score on a scale (calcium score)Definity
Mean calcium score of subjects without major cardiac events at 2 year follow-up45 (16.51 to 73.49)
SecondaryThe Presence of Wall Motion Abnormalities on Definity Stress Echocardiography Assessed for Participants With Both Normal and Abnormal Angiography

In the sub-set of efficacy-evaluable participants who underwent clinically indicated coronary angiography, the accuracy of exercise echocardiography vs. angiography was determined for the detection of CAD. Positive angiography was defined as any stenosis greater than or equal to 50% in any vessel. Wall motion index change indicating abnormal motion was defined as greater than or equal to 13% in 2 or more segments. Angiography was required to have taken place within 60 days following stress echocardiography.

Time frame:
60 days
Reported as:
Count of participants · Participants
The Presence of Wall Motion Abnormalities on Definity Stress Echocardiography Assessed for Participants With Both Normal and Abnormal Angiography
ParticipantsSubjects Undergoing Clinically-indicated Angiography
Subjects w/negative coronary angiography w/o Definity-enhanced stress echo wall motion abnormality7
Subjects w/negative coronary angiography with Definity-enhanced stress echo wall motion abnormality12
Subjects w/positive coronary angiography w/o Definity-enhanced stress echo wall motion abnormality1
Subjects w/positive coronary angiography and Definity-enhanced stress echo wall motion abnormality4
SecondaryParticipants With Positive and Negative Angiography Compared With Their ECG Results

In the sub-set of efficacy-evaluable participants who underwent clinically indicated coronary angiography, the accuracy of exercise ECG vs. angiography was determined for the detection of CAD. Positive angiography was defined as any stenosis greater than or equal to 50% in any vessel.

Time frame:
60 days
Reported as:
Count of participants · Participants
Participants With Positive and Negative Angiography Compared With Their ECG Results
ParticipantsSubjects Undergoing Clinically-indicated Angiography
Subjects negative coronary angiography and negative ECG15
Subjects negative coronary angiography and positive ECG4
Subjects w/positive coronary angiography and negative ECG3
Subjects w/positive coronary angiography and positive ECG2
SecondaryNumber of Participants With Abnormal ECG and With Future Major Adverse Cardiac Events (MACE) at 5 Years Follow-Up

Prognostic value of stress ECG testing for identifying female patients at increased risk of major adverse cardiac events (MACE) at 5-year follow-up Peri- or post-meopausal female participants with an intermediate pre-test likelihood of coronary artery disease (CAD) received resting ECG at baseline. ECG was evaluated as normal or abnormal. The results were compared to patient history on 5-year follow up to identify the potential for ECG to predict those at higher risk of experiencing future major adverse cardiac events (MACE) at 5-year follow up. Major adverse cardiac events (MACE) are defined as * Cardiac death * Myocardial infarction * Cardiac revascularization (PCI or CABG) * Hospitalization for chest pain or to rule out myocardial infarction * Development of typical angina * Development of heart failure

Time frame:
5 year follow up
Reported as:
Number · Percent of participants
Number of Participants With Abnormal ECG and With Future Major Adverse Cardiac Events (MACE) at 5 Years Follow-Up
Percent of participantsDefinity
Percent of subjects with abnormal stress ECG at baseline who had MACE at 5 years16.7
Percent of subjects with abnormal stress ECG at baseline who did not have MACE at 5 years5.0
SecondaryChange in Brain Natriuretic Peptide (BNP) in Participants With and Without Major Adverse Cardiac Events at 5-year Follow-up.

The value of exercise-induced changes in blood concentration of the cardiac peptide, brain natriuretic peptide (BNP in pg/mL in blood), was assessed in identifying patients with cardiac events at 5-year follow-up. The change in mean BNP blood concentration at baseline from rest to stress is summarized using number of participants with and without MACE at 5-year follow up. Major adverse cardiac events (MACE) are defined as * Cardiac death * Myocardial infarction * Cardiac revascularization (PCI or CABG) * Hospitalization for chest pain or to rule out myocardial infarction * Development of typical angina * Development of heart failure

Time frame:
5 year follow up
Reported as:
Mean · pg/mL
Change in Brain Natriuretic Peptide (BNP) in Participants With and Without Major Adverse Cardiac Events at 5-year Follow-up.
pg/mLDefinity
Change of BNP from rest to stress in subjects without major cardiac events at 5 year followup4.9 (0.28 to 9.52)
Change of BNP from rest to stress in subjects with major cardiac events at 5 year followup4.1 (-11.89 to 20.09)
SecondaryChange in Atrial Natriuretic Peptide (ANP) in Participants With and Without Major Adverse Cardiac Events at 5-year Follow-up.

The baseline value of exercise-induced changes in blood concentration of the cardiac peptide, atrial natriuretic peptide (ANP in pg/mL in blood), was assessed in identifying patients with cardiac events at 5-year follow-up. The change in mean ANP blood concentration from rest to stress at baseline was summarized using number of subjects with and without major adverse cardiac events (MACE) at 5-year follow up. Major adverse cardiac events (MACE) are defined as * Cardiac death * Myocardial infarction * Cardiac revascularization (PCI or CABG) * Hospitalization for chest pain or to rule out myocardial infarction * Development of typical angina * Development of heart failure

Time frame:
5 year follow up
Reported as:
Mean · pg/mL
Change in Atrial Natriuretic Peptide (ANP) in Participants With and Without Major Adverse Cardiac Events at 5-year Follow-up.
pg/mLDefinity
Change of ANP from rest to stress in subjects without major cardiac events at 5-year follow-up-37.4 (-165.64 to 90.84)
Change of ANP from rest to stress in subjects with major cardiac events at 5-year follow-up70.5 (-471.2 to 612.2)
SecondaryMean Calcium Score of Participants With and Without Major Cardiac Events at 5-year Follow up.

Coronary artery calcium scoring assesses calcification of the coronary arteries using electron-beam computed tomography (EBCT). It is a sum of lesion scores of area and density above a threshold density. There is no intrinsic upper limit to the calcium score but values above 1000 may not be measurable. A subset of peri- or post-meopausal females with an intermediate pre-test likelihood of coronary artery disease (CAD) received resting EBCT at baseline. Images were evaluated for calcium score and results compared to patient history on 5-year follow up, Mean calcium score with confidence interval was summarized for subjects with and without major cardiac events (MACE) at 5-year follow up Calcium score for general population: Score Description Relative Risk 0 No evidence of CAD 0 1-112 Average Risk of CAD 1.9 100-400 Moderate risk of CAD 4.3 400-999 High risk of CAD 7.2 1000 Very high risk of CAD 10.8

Time frame:
5 year follow up
Reported as:
Mean · score on a scale (calcium score)
Mean Calcium Score of Participants With and Without Major Cardiac Events at 5-year Follow up.
score on a scale (calcium score)Definity
Mean calcium score of subjects without major cardiac events at 5 year follow-up40.2 (14.52 to 65.88)
Mean calcium score of subjects with major cardiac events at 5 year follow-up100 (NA to NA)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Definity—0/400 (0%)6/400 (1.5%)
Most frequent other events
Most frequent other events
EventDefinity
Back PainMusculoskeletal and connective tissue disorders3/400
Back DisorderMusculoskeletal and connective tissue disorders1/400
Muscle SpasmMusculoskeletal and connective tissue disorders1/400
HeadacheNervous system disorders1/400
DyspnoeaRespiratory, thoracic and mediastinal disorders1/400
Urticaria NOSSkin and subcutaneous tissue disorders1/400

Baseline characteristics

Peri- or post-menopausal female subjects between 40 and 65 years of age with an intermediate likelihood of CAD who are scheduled to undergo stress echocardiography

Age, Categorical
Age, Categorical(Participants)Definity
<=18 years0
Between 18 and 65 years394
>=65 years6
Age, Continuous
Age, Continuous(Years)Definity
Mean54.4 (40 to 65)
Sex: Female, Male
Sex: Female, Male(Participants)Definity
Female400
Male0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Definity
American Indian or Alaska Native4
Asian5
Native Hawaiian or Other Pacific Islander0
Black or African American4
White386
More than one race1
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Definity
United States400
08

Study locations

3 sites
  • Local Institution
    Scottsdale, Arizona 85259, United States
  • Local Institution
    Jacksonville, Florida 32224, United States
  • Local Institution
    Rochester, Minnesota 55905, United States
09

References and documents

Publications

  • Abdelmoneim SS, Ball CA, Mantovani F, Hagen ME, Eifert-Rain S, Wilansky S, Castello R, Pellikka PA, Best PJM, Mulvagh SL. Prognostic Utility of Stress Testing and Cardiac Biomarkers in Menopausal Women at Low to Intermediate Risk for Coronary ARTery Disease (SMART Study): 5-Year Outcome. J Womens Health (Larchmt). 2018 May;27(5):542-551. doi: 10.1089/jwh.2017.6506. Epub 2018 Apr 19. PubMed 29672210 ↗
  • Mantovani F, Abdelmoneim SS, Zysek V, Eifert-Rain S, Mulvagh SL. Effect of stress echocardiography testing on changes in cardiovascular risk behaviors in postmenopausal women: a prospective survey study. J Womens Health (Larchmt). 2014 Jul;23(7):581-7. doi: 10.1089/jwh.2013.4604. Epub 2014 Jun 16. PubMed 24932797 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2004, a primary completion of Sep 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2016, 4 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2005
First posted
Sep 13, 2005
Start
Apr 2004
Primary completionActual
Sep 2012
CompletionActual
Oct 2012
Results first posted
Dec 8, 2016
Last update
Mar 15, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00162370
Responsible party
Sponsor
First posted
Sep 13, 2005
Start date
Apr 2004
Primary completion
Sep 2012
Completion
Oct 2012
Results posted
Dec 8, 2016
Last update
Mar 15, 2021

Study contacts

Sharon Mulvagh, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Perflutren

Start the discussion